Pre-made Tefibazumab benchmark antibody (Whole mAb, anti-Staphylococcus aureus fibrin-binding surface epitope clumping factor A (ClfA) therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Anti-Staphylococcus aureus fibrin-binding surface epitope clumping factor A (ClfA) therapeutic antibody (Pre-made Tefibazumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis[1] and of methicillin-resistant S. aureus.[2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1015-1mg	1mg	3090
GMP-Bios-INN-1015-10mg	10mg	Inquiry
GMP-Bios-INN-1015-100mg	100mg	Inquiry
GMP-Bios-INN-1015-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tefibazumab Biosimilar, Whole Mab: Anti-Staphylococcus Aureus Fibrin-Binding Surface Epitope Clumping Factor A (Clfa) therapeutic antibody
INN Name	Tefibazumab
Target	Staphylococcus aureus fibrin-binding surface epitope clumping factor A (ClfA)
Format	Whole mAb
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Inhibitex Inc. (Alpharetta GA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0